Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. (Q27824798)

PubMed

PubMed publication ID

12949711

13 November 2016

title

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

Seiichi Hirota

1

0 references

Akiko Ohashi

2

0 references

Toshirou Nishida

3

0 references

Koji Isozaki

4

0 references

Kazuo Kinoshita

5

0 references

Yasuhisa Shinomura

6

0 references

Yukihiko Kitamura

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

7

0 references

language of work or name

English

0 references

publication date

September 2003

0 references

published in

Gastroenterology

0 references

volume

125

0 references

issue

3

0 references

page(s)

660-7

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Interstitial cells of Cajal generate a rhythmic pacemaker current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Signal transduction by receptors with tyrosine kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2901046-1

10.1016/S0016-5085(03)01046-1

7 January 2021

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

12949711

1 reference

Consolidated OpenCitations Corpus – April 2017